Document is current
Any future updates will be listed below
-
Authors
Mugo, Caroline W
Church, Ella
Horniblow, Richard D
Mollan, Susan P
Botfield, Hannah
Hill, Lisa J
Sinclair, Alexandra J
Grech, Olivia
-
Funding
Funding for this research was provided by:
Sir Jules Thorn Charitable Trust
Pain Relief Foundation
- License Information
-
More Information
Article History
Received: 20 February 2025
Accepted: 16 April 2025
First Online: 21 May 2025
Declarations
:
: Not applicable.
: Not applicable.
: Alexandra Sinclair reports has consulted for Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva Uk and Novartis. She was previously a Director and Chief Scientific Officer (CSO) with shares at Invex Therapeutics.
